Bioplex technology: Novel synthetic gene delivery pharmaceutical based on peptides anchored to nucleic acids

Current Pharmaceutical Design

Volumn 11, Issue 28, 2005, Pages 3671-3680

  Simonson, Oscar E ^a   Svahn, Mathias G ^a   Törnquist, Elizabeth ^a   Lundin, Karin E ^a   Smith, C I E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bioplex; Gene therapy; Non viral vectors; Peptide nucleic acid; PLasmids

Indexed keywords

ADENOVIRUS VECTOR; ASIALOFETUIN; ASIALOGLYCOPROTEIN RECEPTOR; CALCIUM ION; CARBOHYDRATE; CATHEPSIN L; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DNA HYBRID; EDETIC ACID; GALACTOSE; HYBRID PROTEIN; KARYOPHERIN ALPHA; KARYOPHERIN BETA; LECTIN; LENTIVIRUS VECTOR; LOCKED NUCLEIC ACID; LYSINE; N ACETYLGALACTOSAMINE; NAKED DNA; OLIGONUCLEOTIDE; OLIGOSACCHARIDE; PEPTIDE NUCLEIC ACID; PLASMID DNA; PLASMID VECTOR; PROTEIN SUBUNIT; PROTEINASE; RETROVIRUS VECTOR; SMALL INTERFERING RNA; STREPTAVIDIN; TRANSACTIVATOR PROTEIN; TRIACYLGLYCEROL; UNINDEXED DRUG;

AMINO ACID SEQUENCE; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DISEASE SEVERITY; DNA DETERMINATION; DNA HYBRIDIZATION; DNA POLYMORPHISM; DNA SEQUENCE; DOSE RESPONSE; DRUG BINDING SITE; DRUG DESIGN; DRUG DETERMINATION; DRUG MEGADOSE; DRUG RESEARCH; ENDOCYTOSIS; ENZYME ACTIVITY; FUNCTIONAL ASSESSMENT; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE INSERTION; GENE TARGETING; GENE TRANSFER; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS 1; HUMAN; IN VIVO STUDY; INTERMETHOD COMPARISON; LEUKEMOID REACTION; LIGAND BINDING; MACROMOLECULE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; NUCLEAR PORE COMPLEX; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STABILITY; RECEPTOR AFFINITY; RECEPTOR BLOCKING; REVIEW; SIMIAN VIRUS; TARGET CELL; TARGET ORGAN;

ANIMALS; ASIALOGLYCOPROTEINS; CELL NUCLEUS; COMBINATORIAL CHEMISTRY TECHNIQUES; DNA; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; LIVER; NUCLEAR PORE COMPLEX PROTEINS; PEPTIDE NUCLEIC ACIDS; PEPTIDES;

EID: 27744445785     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774580813     Document Type: Review

References (84)

1. Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet 2000; 1(2): 91-9.
2. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4(5): 346-58.
3. Blomberg P, Smith CI. Gene therapy of monogenic and cardiovascular disorders. Exp Opin Biol Ther 2003; 3(6): 941-9.
4. Cone RD, Mulligan RC. High-efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad mammalian host range. Proc Natl Acad Sci USA 1984; 81(20): 6349-53.
5. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 1995; 270(5235): 475-80.
6. Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther 1998; 80(1): 35-47.
7. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F., Wulffraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348(3): 255-6.
8. Lai CM, Lai YK, Rakoczy PE. Adenovirus and adeno-associated virus vectors. DNA Cell Biol 2002; 21(12): 895-913.
9. Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol 2000; 18(1): 33-7.
10. Barquinero J, Eixarch H, Perez-Melgosa M. Retroviral vectors: new applications for an old tool. Gene Ther 2004; 11 Suppl 1: S3-9.
11. Recombinant DNA research: actions under the guidelines; notice. Fed Regist 1995; 60(81): 20726-37.
12. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288(5466): 669-72.
13. Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001; 8(4): 308-15.
14. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF 121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100(5): 468-74.
15. Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science 2004; 303(5656): 333.
16. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296(5577): 2410-3.
17. Herzog RW, Arruda VR. Update on gene therapy for hereditary hematological disorders. Expert Rev Cardiovasc Ther 2003; 1(2): 215-32.
18. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80(1-2): 148-58.
19. Sze DY, Freeman SM, Slonim SM, Samuels SL, Andrews JC, Hicks M, et al. Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival. J Vasc Interv Radiol 2003; 14(3): 279-90.
20. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10(10): 1735-7.
21. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6(7): 1258-66.
22. Herweijer H, Wolff JA. Progress and prospects: naked DNA gene transfer and therapy. Gene Ther 2003; 10(6): 453-8.
23. Kren BT, Bandyopadhyay P, Steer CJ. In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides, Nat Med 1998; 4(3): 285-90.
24. Zhang X, Sawyer GJ, Dong X, Qiu Y, Collins L, Fabre JW. The in vivo use of chloroquine to promote non-viral gene delivery to the liver via the portal vein and bile duct. J Gene Med 2003; 5(3): 209-18.
25. Greelish JP, Su LT, Lankford EB, Burkman JM, Chen H. Konig SK, et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med 1999; 5(4): 439-43.
26. Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004; 10(8): 828-34.
27. Branden LJ, Smith CI. Bioplex technology: novel synthetic gene delivery system based on peptides anchored to nucleic acids. Methods Enzymol 2002; 346: 106-24.
28. Svahn MG, Lundin KE, Ge R, Tornquist E, Simonson EO, Oscarsson S, et al. Adding functional entities to plasmids. J Gene Med 2004; 6 Suppl 1: S36-44.
29. Nielsen PE. Peptide nucleic acids as therapeutic agents. Curr Opin Struct Biol 1999; 9(3): 353-7.
30. Pooga M, Soomets U, Hallbrink M, Valkna A, Saar K, Rezaei K, et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol 1998; 16(9): 857-61.
31. Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991; 254(5037): 1497-500.
32. Nielsen PE. PNA technology. Methods Mol Biol 2002; 208: 3-26.
33. Egholm M, Christensen L, Dueholm KL, Buchardt O, Coull J, Nielsen PE. Efficient pH-independent sequence-specific DNA binding by pseudoisocytosine-containing bis-PNA. Nucleic Acids Res 1995; 23(2): 217-22.
34. Lohse J, Dahl O, Nielsen PE. Double duplex invasion by peptide nucleic acid: a general principle for sequence-specific targeting of double-stranded DNA. Proc Natl Acad Sci USA 1999; 96(21): 11804-8.
35. Demidov VV, Protozanova E, Izvolsky KI, Price C, Nielsen PE, Frank-Kamenetskii MD. Kinetics and mechanism of the DNA double helix invasion by pseudocomplementary peptide nucleic acids. Proc Nad Acad Sci USA 2002; 99(9): 5953-8.
36. Braasch DA, Corey DR. Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem Biol 2001; 8(1): 1-7.
37. Petersen M, Wengel J. LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol 2003; 21(2): 74-81.
38. Kurreck J, Wyszko E, Gillen C, Erdmann VA. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res 2002; 30(9): 1911-8.
39. Crinelli R, Bianchi M, Gentilini L, Magnani M. Design and characterization of decoy oligonucleotides containing locked nucleic acids. Nucleic Acids Res 2002; 30(11): 2435-43.
40. Simeonov A, Nikiforov TT. Single nucleotide polymorphism genotyping using short, fluorescently labeled locked nucleic acid (LNA) probes and fluorescence polarization detection. Nucleic Acids Res 2002; 30(17): e9l.
41. Demidov VV. PNA and LNA throw light on DNA. Trends Biotechnol 2003; 21(1): 4-7.
42. Wahlestedt C, Salmi P, Good L, Kela J, Johnsson T, Hokfelt T, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 2000; 97(10): 5633-8.
43. Hertoghs KM, Ellis JH, Catchpole IR. Use of locked nucleic acid oligonucleotides to add functionality to plasmid DNA. Nucleic Acids Res 2003; 31(20): 5817-30.
44. Lundin KE, Ge R, Svahn MG, Tornquist E, Leijon M, Branden LJ, et al. Cooperative strand invasion of supercoiled plasmid DNA by mixed linear PNA and PNA-peptide chimeras. Biomol Eng 2004; 21(2): 51-9.
45. Kurakin A, Larsen HJ, Nielsen PE. Cooperative strand displacement by peptide nucleic acid (PNA). Chem Biol 1998; 5(2): 81-9.
46. Lundin KE, Hasan M, Moreno PM, Tornquist E, Oprea I, Svahn MG, et al. Increased stability and specificity by combined Peptide Nucleic Acid (PNA) and Locked Nucleic Acid (LNA) Hybridization to super coiled plasmids for PNA-anchored "Bioplex" formation. Biomol Eng 2005; in press.
47. Kawasaki T, Ashwell G. Chemical and physical properties of an hepatic membrane protein that specifically binds asialoglycoproteins. J Biol Chem 1976; 251(5): 1296-302.
48. Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev 1995; 75(3): 591-609.
49. Geffen I, Spiess M. Asialoglycoprotein receptor. Int Rev Cytol 1992; 137B: 181-219.
50. Joziasse DH, Lee RT, Lee YC, Biessen EA, Schiphorst WE, Koeleman CA, et al. alpha3-galactosylated glycoproteins can bind to the hepatic asialoglycoprotein receptor. Eur J Biochem 2000; 267(21): 6501-8.
51. Rice KG, Weisz OA, Barthel T, Lee RT, Lee YC. Defined geometry of binding between triantennary glycopeptide and the asialoglycoprotein receptor of rat heptocytes. J Biol Chem 1990; 265(30): 18429-34.
52. Kichler A, Schuber F. Versatile synthesis of bi- and tri-antennary galactose ligands: interaction with the Gal/GalNAc receptor of human hepatoma cells. Glycoconj J 1995; 12(3): 275-81.
53. Kichler A, Schuber F. Comparative affinity of synthetic multi-antennary galactosyl derivatives for the Gal/GalNAc receptor of rat hepatocytes and peritoneal macrophages. J Drug Target 1998; 6(3): 201-5.
54. Biessen EA, Vietsch H, Van Berkel TJ. Cholesterol derivative of a new triantennary cluster galactoside directs low- and high-density lipoproteins to the parenchymal liver cell. Biochem J 1994; 302 ( Pt 1): 283-9.
55. van Berkel TJ, Kruijt JK, Spanjer HH, Nagelkerke JF, Harkes L, Kempen HJ. The effect of a water-soluble tris-galactoside-terminated cholesterol derivative on the fate of low density lipoproteins and liposomes. J Biol Chem 1985; 260(5): 2694-9.
56. Singh M, Ariatti M. Targeted gene delivery into HepG2 cells using complexes containing DNA, cationized asialoorosomucoid and activated cationic liposomes. J Control Release 2003; 92(3): 383-94.
57. Schwartz AL, Fridovich SE, Knowles BB, Lodish HF. Characterization of the asialoglycoprotein receptor in a continuous hepatoma line. J Biol Chem 1981; 256(17): 8878-81.
58. Spiess M. The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry 1990; 29(43): 10009-18.
59. van Rossenberg SM, Sliedregt-Bol KM, Koning G, van den Elst H, van Berkel TJ, van Boom JH, et al. Improvement of hepatocyte-specific gene expression by a targeted colchicine prodrug. Chembiochem 2003; 4(7): 633-9.
60. van Rossenbeig SM, Sliedregt-Bol KM, Prince P, van Berkel TJ, van Boom JH, van der Marel GA, et al. A targeted peptide nucleic acid to down-regulate mouse microsomal triglyceride transfer protein expression in hepatocytes. Bioconjug Chem 2003; 14(6): 1077-82.
61. Westerlind U, Westman J, Tornquist E, Smith CI, Oscarson S, Lahmann M, et al. Ligands of the asialoglycoprotein receptor for targeted gene delivery, part 1: Synthesis of and binding studies with biotinylated cluster glycosides containing N-acetylgalactosamine. Glycoconj J 2004; 21(5): 227-41.
62. Wilson JM. Vectors - shuttle vehicles for gene therapy. Clin Exp Immunol 1997; 107 Suppl 1: 31-2.
63. Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 1995; 270(32): 18997-9007.
64. Roth CM, Sundaram S. Engineering synthetic vectors for improved DNA delivery: insights from intracellular pathways. Annu Rev Biomed Eng 2004; 6: 397-426.
65. Capecchi MR. High efficiency transformation by direct microinjection of DNA into cultured mammalian cells. Cell 1980; 22(2 Pt 2): 479-88.
66. Lukacs GL, Haggie P, Seksek O, Lechardeur D, Freedman N, Verkman AS. Size-dependent DNA mobility in cytoplasm and nucleus. J Biol Chem 2000; 275(3): 1625-9.
67. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93(21): 11382-8.
68. Ryan KJ, Wente SR. The nuclear pore complex: a protein machine bridging the nucleus and cytoplasm. Curr Opin Cell Biol 2000; 12(3): 361-71.
69. Jans DA, Chan CK, Huebner S. Signals mediating nuclear targeting and their regulation: application in drug delivery. Med Res Rev 1998; 18(4): 189-223.
70. Conti E, Izaurralde E. Nucleocytoplasmic transport enters the atomic age. Curr Opin Cell Biol 2001; 13(3): 310-9.
71. Imamoto N. Diversity in nucleocytoplasmic transport pathways. Cell Struct Funct 2000; 25(4): 207-16.
72. Whittaker GR, Kann M, Helenius A. Viral entry into the nucleus. Annu Rev Cell Dev Biol 2000; 16: 627-51.
73. Branden LJ, Mohamed AJ, Smith CI. A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nat Biotechnol 1999; 17(8): 784-7.
74. Branden LJ, Christensson B, Smith CI. In vivo nuclear delivery of oligonucleotides via hybridizing bifunctional peptides. Gene Ther 2001; 8(1): 84-7.
75. Bremner KH, Seymour LW, Logan A, Read ML. Factors influencing the ability of nuclear localization sequence peptides to enhance nonviral gene delivery. Bioconjug Chem 2004; 15(1): 152-61.
76. Vaysse L, Harbottle R, Bigger B, Bergau A, Tolmachov O, Coutelle C. Development of a self-assembling nuclear targeting vector system based on the tetracycline repressor protein. J Biol Chem 2004; 279(7): 5555-64.
77. Zanta MA, Belguise-Valladier P, Behr JP. Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc Natl Acad Sci USA 1999; 96(1): 91-6.
78. Svahn MG, Salih G, Simonson EO, Smith CI, Branden LJ. Protease-induced release of functional peptides from bioplexes. J Control Release 2004; 98(1): 169-77.
79. Yi Y, Lee C, Liu QH, Freedman BD, Collman RG. Chemokine receptor utilization and macrophage signaling by human immunodeficiency virus type 1 gp120: Implications for neuropathogenesis. J Neurovirol 2004; 10 Suppl 1: 91-6.
80. Meier O, Greber UF. Adenovirus endocytosis. J Gene Med 2004; 6 Suppl 1: S152-63.
81. Arteaga HJ, Hinkula J, van Dijk-Hard I, Dilber MS, Wahren B, Christensson B, et al. Choosing CCR5 or Rev siRNA in HIV-1. Nat Biotechnol 2003; 21(3): 230-1.
82. Abraham NG. Therapeutic applications of human heme oxygenase gene transfer and gene therapy. Curr Pharm Design 2003; 9(30): 2513-24.
83. Ast G. Drug-targeting strategies for prostate cancer. Curr Pharm Design 2003; 9(6): 455-66.
84. Xodo LE, Cogoi S, Rapozzi V. Anti-gene strategies to down-regulate gene expression in mammalian cells. Curr Pharm Design 2004; 10(7): 805-19.